The association between excessive alcohol consumption and liver disease is well documented. In fact, the effect on alcohol consumption levels during the COVID-19 pandemic has more recently been investigated. In a 2022 Hepatology article, researchers estimated that the one-year increase in alcohol consumption during the pandemic would result in an …
European Society for Medical Oncology: Understanding barriers to accessible cancer care
The European Society for Medical Oncology (ESMO) recently held its first in-person congress since the COVID-19 pandemic. The conference, held in Paris, brought together more than 22,000 attendees to share and discuss the latest evidence and issues in cancer care. A common thread running through the congress program was ESMO’s …
snapClinical® team launches eSource module to revolutionize at-home care for Labcorp Drug Development Mobile Clinical Services
This is a special edition of the Labcorp Drug Development Decentralized Clinical Trial (DCT) blog. Labcorp Drug Development Mobile Clinical Services (MCS) team has now completed the first global visit utilizing the eSource module of the proprietary Labcorp DCT platform, snapClinical. This module represents a cross-functional effort to develop a …
Balancing precision and recall in the pharmacovigilance (PV) literature monitoring
What do precision and recall mean in lay terms? In pattern recognition, information retrieval and classification (machine learning), precision and recall are performance metrics that apply to data retrieved from a collection, corpus or sample space. Precision (also called positive predictive value) is the fraction of relevant instances among the retrieved instances, while recall (also known as sensitivity) is the fraction of relevant instances that were retrieved. …
Application of decentralized clinical trials on AI-focused dermatology
Leveraging AI-focused dermatology in decentralized clinical trials The use of virtual tools and telecommunications skyrocketed during the COVID-19 pandemic as the world adjusted to new ways of working. In the clinical trials sector, this propelled an increasing adaptation to the decentralized clinical trial (DCT) approach to support research and minimize …
NHS England’s Rare Disease Action Plan: Renewed focus on access to innovative drugs
In England, February 2022 has seen the lifting of all COVID-19 restrictions. As we cautiously enter a “new normal” after the disruption caused by the pandemic, there is renewed focus on previous healthcare priorities. The development and commercialization of innovative treatments for rare diseases has long been an area of …
Labcorp Patient Access Solutions Asembia discussions for 2022
Marking progress since Asembia 2021 At industry events, there are the discussions you hear inside of sessions, and there are also the discussions that take place outside of sessions. During the October 2021 Asembia event, we heard several common themes among attendees, clients, prospects and vendors: Balancing digital innovation and …
The July 2021 edition of the Labcorp Drug Development Decentralized Clinical Trials blog
In our previous edition of the blog, we highlighted our upcoming presence at DIA. Our focus at the show this year was patient diversity, patient equity, and patient engagement. The recordings from the show are now available, so this month we will point you toward those in case you missed …
Decentralized Clinical Trials (DCT) Monthly Blog – May 2021
This month in the DCT Blog, we are going to put the spotlight on several events coming up in the next few weeks.
Webinar: Advancing Your Neurodegenerative Biomarker Strategy Beyond Discovery
On April 15, we hosted the virtual conference, “Advancing Your Neurodegenerative Biomarker Strategy Beyond Discovery.” For study teams working to develop treatments for patients suffering from neurodegenerative diseases, the need to leverage new techniques quickly and effectively is imperative. This topic is vital, as nearly 50 million people worldwide suffer …